Craniopharyngioma medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Although systemic therapy is generally not utilized, a small series has shown that the use of subcutaneous pegylated interferon alpha-2b to manage ''cystic recurrences'' can result in durable responses. | Although systemic therapy is generally not utilized, a small series has shown that the use of '''subcutaneous pegylated interferon alpha-2b''' to manage ''cystic recurrences'' can result in durable responses. | ||
==References== | ==References== | ||
Revision as of 18:31, 23 August 2015
|
Craniopharyngioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Craniopharyngioma medical therapy On the Web |
|
American Roentgen Ray Society Images of Craniopharyngioma medical therapy |
|
Risk calculators and risk factors for Craniopharyngioma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Patients with craniopharyngioma have many treatment options. The selection depends on the size, location of the tumor. The options are surgery, radiation therapy, chemotherapy, or a combination of these methods.
Medical Therapy
Although systemic therapy is generally not utilized, a small series has shown that the use of subcutaneous pegylated interferon alpha-2b to manage cystic recurrences can result in durable responses.